Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 7, 2012; 18(45): 6577-6586
Published online Dec 7, 2012. doi: 10.3748/wjg.v18.i45.6577
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Immunohistochemical analysis of human epidermal growth factor receptor 2 in gastric cancer tissues. A: Human epidermal growth factor receptor 2 (HER2) 3+; B: HER2 2+; C: HER2 1+; D: HER2 0. Original magnification, ×200.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide mutations detected by pyrosequencing in gastric cancer tissues. A: Exon1 RS1 wild type; B: 263G>A (R88Q) mutation; C: Exon1 RS2 wild type; D: 323G>A (R108H) mutation.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 In situ hybridization analysis of Epstein-Barr virus-encoded small RNA-1 and human epidermal growth factor receptor 2 immunohistochemical expression in gastric cancer tissues. A: Gastric adenocarcinoma positive for Epstein-Barr virus-encoded small RNA-1 (EBER-1); B: Gastric adenocarcinoma negative for EBER-1; C: Immunohistochemical analysis of human epidermal growth factor receptor 2 (HER2) in an Epstein-Barr virus-positive and HER2-positive case. Original magnification, ×200.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Immunohistochemical analysis and assessment of phospho Akt positivity based on molecular alterations in gastric cancer tissues. A: Gastric adenocarcinoma showing phospho Akt (pAkt) positivity. Original magnification, ×200; B: pAkt expression significantly correlates with human epidermal growth factor receptor 2 (HER2) overexpression (P < 0.01) but not with phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (PIK3CA) mutations (P = 0.37) or Epstein-Barr virus (EBV) infection (P = 0.69).
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Survival analysis of gastric cancer patients. Three year survival of human epidermal growth factor receptor 2 (HER2)-positive vs HER2-negative, 29.1 mo vs 59.4 mo; Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (PIK3CA) mutation vs wild type, 63.7 mo vs 56.3 mo; Epstein-Barr virus (EBV)-positive vs EBV-negative, 51.3 mo vs 57.6 mo; And phospho Akt (pAkt)-positive vs pAkt-negative, 50.7 mo vs 64.8 mo. Five year survival of pAkt-positive vs pAkt-negative cases, 35.5 mo vs 58.1 mo.